BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32775432)

  • 1. Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
    Fang YJ; Chung YL; Lin CL; Lim YP
    Biomed Res Int; 2020; 2020():6358954. PubMed ID: 32775432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
    Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
    PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
    Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
    Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on
    Fang YJ; Wu TY; Lin CL; Su CY; Li JR; Chung YL; Tien N; Lim YP
    Mediators Inflamm; 2020; 2020():8890300. PubMed ID: 33273891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
    Lin KH; Yen FS; Li HL; Wei JC; Hsu CC; Yang CC; Hwu CM
    J Hum Hypertens; 2021 Apr; 35(4):351-359. PubMed ID: 32366929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
    Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
    Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
    Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
    PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
    Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
    Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
    Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
    Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
    Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
    Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
    Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.
    Kwok TSH; Kuriya B; Hawker G; Li P; Choy G; Widdifield J
    Arthritis Care Res (Hoboken); 2023 Dec; 75(12):2463-2471. PubMed ID: 37248652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of allopurinol use on urate concentration and cardiovascular outcome.
    Wei L; Mackenzie IS; Chen Y; Struthers AD; MacDonald TM
    Br J Clin Pharmacol; 2011 Apr; 71(4):600-7. PubMed ID: 21395653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study.
    Chen JH; Lan JL; Cheng CF; Liang WM; Lin HY; Tsay GJ; Yeh WT; Pan WH
    J Rheumatol; 2015 Sep; 42(9):1694-701. PubMed ID: 26077411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
    Zhang X; Tang Y; Wang M; Wang D; Li Q
    Clin Rheumatol; 2021 Feb; 40(2):701-710. PubMed ID: 32562072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
    Wei J; Choi HK; Dalbeth N; Lane NE; Wu J; Lyu H; Zeng C; Lei G; Zhang Y
    Arthritis Rheumatol; 2023 Aug; 75(8):1456-1465. PubMed ID: 36940260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden and management of gout in a multi-ethnic Asian cohort.
    Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
    Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.